| Adaptive designs in clinical trials: why use them, and how to run and report them P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ... BMC medicine 16 (1), 1-15, 2018 | 517 | 2018 |
| Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme SJ Walters, IB dos Anjos Henriques-Cadby, O Bortolami, L Flight, D Hind, ... BMJ open 7 (3), e015276, 2017 | 314 | 2017 |
| Adaptive designs undertaken in clinical research: a review of registered clinical trials I Hatfield, A Allison, L Flight, SA Julious, M Dimairo Trials 17 (1), 1-13, 2016 | 107 | 2016 |
| Practical guide to sample size calculations: non‐inferiority and equivalence trials L Flight, SA Julious Pharmaceutical statistics 15 (1), 80-89, 2016 | 97 | 2016 |
| The disagreeable behaviour of the kappa statistic L Flight, SA Julious Pharmaceutical statistics 14 (1), 74-78, 2015 | 77 | 2015 |
| Practical guide to sample size calculations: an introduction L Flight, SA Julious Pharmaceutical statistics 15 (1), 68-74, 2016 | 46 | 2016 |
| Appropriate statistical methods for analysing partially nested randomised controlled trials with continuous outcomes: a simulation study J Candlish, MD Teare, M Dimairo, L Flight, L Mandefield, SJ Walters BMC medical research methodology 18 (1), 1-17, 2018 | 39 | 2018 |
| Recommendations for the analysis of individually randomised controlled trials with clustering in one arm–a case of continuous outcomes L Flight, A Allison, M Dimairo, E Lee, L Mandefield, SJ Walters BMC Medical Research Methodology 16 (1), 1-13, 2016 | 38 | 2016 |
| A review of clinical trials with an adaptive design and health economic analysis L Flight, F Arshad, R Barnsley, K Patel, S Julious, A Brennan, S Todd Value in Health 22 (4), 391-8, 2019 | 25 | 2019 |
| Practical guide to sample size calculations: superiority trials L Flight, SA Julious Pharmaceutical statistics 15 (1), 75-79, 2016 | 18 | 2016 |
| Point estimation for adaptive trial designs I: A methodological review DS Robertson, B Choodari‐Oskooei, M Dimairo, L Flight, P Pallmann, ... Statistics in medicine 42 (2), 122-145, 2023 | 15 | 2023 |
| How can health economics be used in the design and analysis of adaptive clinical trials? A qualitative analysis L Flight, S Julious, A Brennan, S Todd, D Hind Trials 21 (1), 1-12, 2020 | 12 | 2020 |
| Point estimation for adaptive trial designs I: a methodological review DS Robertson, B Choodari-Oskooei, M Dimairo, L Flight, P Pallmann, ... arXiv preprint arXiv:2105.08836, 2021 | 10 | 2021 |
| Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial BM Pennington, M Hernández-Alava, P Hykin, S Sivaprasad, L Flight, ... Value in Health 23 (7), 928-935, 2020 | 8 | 2020 |
| Expected value of sample information to guide the design of group sequential clinical trials L Flight, S Julious, A Brennan, S Todd Medical Decision Making 42 (4), 461-473, 2022 | 7 | 2022 |
| Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. P Hykin, AT Prevost, S Sivaprasad, JC Vasconcelos, C Murphy, J Kelly, ... Health Technology Assessment (Winchester, England) 25 (38), 1-196, 2021 | 7 | 2021 |
| Comprehensive review of statistical methods for analysing patient-reported outcomes (PROs) used as primary outcomes in randomised controlled trials (RCTs) published by the UK’s … Y Qian, SJ Walters, R Jacques, L Flight BMJ open 11 (9), e051673, 2021 | 6 | 2021 |
| Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study B Pennington, A Alshreef, L Flight, A Metry, E Poku, P Hykin, ... PharmacoEconomics 39 (8), 913-927, 2021 | 6 | 2021 |
| The use of health economics in the design and analysis of adaptive clinical trials L Flight University of Sheffield, 2020 | 6 | 2020 |
| Can emergency medicine research benefit from adaptive design clinical trials? L Flight, SA Julious, S Goodacre Emerg Med J 34 (4), 243-248, 2017 | 5 | 2017 |
